Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Gains from Sales and Divestitures (2022)

Fennec Pharmaceuticals (FENC) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $26000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Gains from Sales and Divestitures changed N/A year-over-year to $26000.0, compared with a TTM value of $26000.0 through Dec 2022, changed N/A, and an annual FY2022 reading of $26000.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $26000.0 for Q4 2022 at Fennec Pharmaceuticals.
  • Across five years, Gains from Sales and Divestitures topped out at $26000.0 in Q4 2022 and bottomed at $26000.0 in Q4 2022.